| Identification | Back Directory | [Name]
N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT | [CAS]
51116-00-8 | [Synonyms]
DB-cGMP
DBCGMP NA
Bt2cGMP sodium
DIBUTYRYL-CGMP
DIBUTYRYL-CGMP NA
DB-CGMP SODIUM SALT
Dibutyryl-cGMP sodium
N2,2'-O-Dibutyryl cGMP
DIBUTYRYL-CGMP SODIUM SALT
MGBPJXVWDGGLKI-GBIKJYCISA-M
Dibutyryl-Cyclic GMP (sodium salt)
N2 2'-O-DIBUTYRYLGUANOSINE-3' 5'-CYCLO-&
N,2'-O-Dibutyrylguanosine 3',5'-phosphoric acid
N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPH
dibutyryl cyclic 3',5'-guanosine monophosphate, sodium
Guanosine, 3,5-cyclic Monophosphate, N2,2-O-Dibutyryl-,
N2,2'-O-dibutyrylguanosine-3',5'-cyclo-phos. so-sa. dihyd.
N2-2''-O-Dibutyrylguanosine-3'',5''-cyclic monophosphoric acid
N2,2'-O-DIBUTYRYLGUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT
N2,2'-O-DIBUTYRYLGUANOSINE-3',5'-CYCLIC MONOPHOSPHATE SODIUM SALT
GUANOSINE 3',5'-CYCLIC MONOPHOSPHATE, N2,2'-O-DIBUTYRYL-, SODIUM SALT
n2,2’-o-dibutyrylguanosine-3’,5’-cyclicmonophosphate(dbcgmp),sodiumsalt
N2,2-O-Dibutyrylguanosine 3,5-cyclic monophosphate sodium salt dihydrate
N2,2μ-O-Dibutyrylguanosine 3μ,5μ-cyclic monophosphate hydrate sodium salt
N2,2μ-O-Dibutyrylguanosine 3μ,5μ-cyclic monophosphate dihydrate sodium salt
Guanosine, N-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate) 2'-butanoate, monosodium salt
Guanosine 3,5-cyclic Monophosphate, N2,2-O-Dibutyryl-, Sodium Salt - CAS 51116-00-8 - Calbiochem | [EINECS(EC#)]
256-992-2 | [Molecular Formula]
C18H23N5NaO9P | [MDL Number]
MFCD00038422 | [MOL File]
51116-00-8.mol | [Molecular Weight]
507.37 |
| Hazard Information | Back Directory | [Description]
Dibutyryl-cyclic GMP (dibutyryl-cGMP) is a cell-permeable, cGMP analog that activates cGMP-dependent protein kinase. It has been used in a wide variety of research applications to mimic cGMP interactions and effects on different biological molecules. | [Uses]
Dibutyryl-cGMP is a membrane permeable cGMP analog. | [in vivo]
Dibutyryl-cGMP (50-200?μg/paw; subcutaneous injection; male Wistar rats) treatment antagonizes the hyperalgesic effect of PGE2 in a dose-dependent manner. Maximal antinociceptive effect of DbcGMP is at 1?h after administration and last for plus 2?h[3]. | Animal Model: | Male Wistar rats (180-?250?g) injection with Prostaglandin E2 (PGE2)[3] | | Dosage: | 50 μg/paw, 75 μg/paw, 100 μg/paw and 200?μg/paw | | Administration: | Subcutaneous injection | | Result: | Antagonized the hyperalgesic effect of PGE2 (2?μg/paw), in a dose-dependent manner.
|
| [References]
[1] M. CATALDI . Involvement of phosphodiesterase-cGMP-PKG pathway in intracellular Ca2+ oscillations in pituitary GH3 cells[J]. Biochimica et biophysica acta. Molecular cell research, 1999, 1449 2: Pages 186-193. DOI: 10.1016/s0167-4889(99)00013-0
[2] NICHOLAS J. WILLMOTT Antony G Judith Asselin. Calcium store depletion potentiates a phosphodiesterase inhibitor- and dibutyryl cGMP-evoked calcium influx in rat pituitary GH3 cells[J]. FEBS Letters, 1996, 386 1: 39-42. DOI: 10.1016/0014-5793(96)00413-9
[3] S S KAPLAN. Inhibition of chemotaxis Ng-monomethyl-L-arginine: a role for cyclic GMP.[J]. Blood, 1989, 74 6: 1885-1887.
[4] C. CHIK. cGMP inhibits L-type Ca2+ channel currents through protein phosphorylation in rat pinealocytes[J]. Journal of Neuroscience, 1995, 2 1: 3104-3109. DOI: 10.1523/jneurosci.15-04-03104.1995
[5] T A ROONEY. Cyclic GMP induces oscillatory calcium signals in rat hepatocytes.[J]. The Journal of Biological Chemistry, 1996, 271 33: 19817-19825. DOI: 10.1074/jbc.271.33.19817 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList1701258/0_EN.htm |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|